Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV
J. Medraño, Vincent Soriano(Fundación Instituto Valenciano de Oncología), Salvador Resino(Instituto de Salud Carlos III), Karin Neukam(Hospital Universitario de Valme), Antonio Rivero(University of Southern California), Susanna Naggie(Duke University), Carlos Sánchez‐Piedra, Norma Rallón(Hospital Universitario Rey Juan Carlos), José M. Benito(Hospital Universitario Rey Juan Carlos), John G. McHutchison(Gilead Sciences (United States)), Aida Calviño(Instituto de Salud Carlos III), Juan A. Pineda(Hospital Universitario de Valme), Eugenia Vispo, Pablo Barreiro(Hospital Clínico San Carlos), Antonio Carúz(Universidad de Jaén), Juan Macı́as(Hospital Universitario de Valme)
Cited by 57
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k